Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21993938 | 1.00 | SIGMAR1 (0.47) | SIGMAR1KDM1ACYP3A4UGCGTACR1 | |
| SCHEMBL28964369 | 0.81 | SIGMAR1 (0.46) | SIGMAR1KDM1AKDM4CBACE1DRD2 | |
| SCHEMBL21930565 | 0.78 | SIGMAR1 (0.42) | SIGMAR1KDM1AKDM4CBACE1 | |
| SCHEMBL21930213 | 0.78 | SIGMAR1 (0.42) | SIGMAR1KDM1AKDM4CBACE1 | |
| SCHEMBL23442097 | 0.74 | KDM1A (0.41) | SIGMAR1KDM1AKDM4CBACE1 | |
| SCHEMBL17542382 | 0.71 | ALDH1A1 (0.38) | SIGMAR1KDM1AKDM4C | |
| SCHEMBL17542383 | 0.71 | ALDH1A1 (0.38) | SIGMAR1KDM1AKDM4C | |
| SCHEMBL17542332 | 0.70 | KDM1A (0.37) | SIGMAR1KDM1AKDM4C | |
| SCHEMBL17542330 | 0.70 | KDM1A (0.37) | SIGMAR1KDM1AKDM4C | |
| SCHEMBL26194440 | 0.70 | SMN1; SMN2 (0.39) | SIGMAR1KDM1AKDM4CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | SIGMAR1 2212/4885KDM1A 1749/4885CYP3A4 4140/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | SIGMAR1 2212/4885KDM1A 1749/4885CYP3A4 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.